Cardiac catheterization is the gold standard method for determining coronary artery disease and providing percutaneous intervention. Access is obtained by advancing catheters via sheaths mostly in femoral and radial arteries. For hemostasis, manual compression at the access site may cause patient discomfort including severe pain. Femoral artery closure devices were introduced as an alternative to compression. Although bleeding and vascular complication rates with these devices are similar to manual compression, infection is a more serious complication of closure devices. We present a rare case of infection, which turned into complex pseudo aneurysm and discuss treatment and plan for avoiding future device-associated infections.

©2013 The Authors. Published by the JScholar under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/3.0/, which permits unrestricted use, provided the original author and source are credited.
Case report

We present a 76-year-old male with history of coronary artery disease status post coronary artery bypass graft surgery (single left internal mammary artery bypass to the left anterior descending artery) in 2009, hypertension, and diabetes mellitus type II, who presented to the Emergency Department (ED) with left shoulder pain that radiated to his left jaw and down his left arm, very similar in character which led to his bypass surgery. His cardiac enzymes were normal and his electrocardiogram was negative for ischemia. Myocardial perfusion scan demonstrated severe and extensive defect in the basal and mid inferior, inferolateral, and inferoseptal area compatible with old infarction and mild peri-infarct ischemia. As this perfusion defect was different than that expected for his prior CAD, he was brought to the cardiac catheterization laboratory for further evaluation. Using electrical clippers for removing hair and chlorhexidine for skin sterilization, the right groin was prepped. Using appropriate sterile techniques, cardiac catheterization was performed using a modified Seldinger technique through a 5 Fr sheath introduced into the right common femoral artery. Angiographic results did not reveal any significant stenosis in the native coronary arteries or in the bypass graft. Immediately after the angiogram, entry site at the common femoral artery and absence of significant atherosclerosis were documented by limited femoral angiography, and a 6 Fr Angio-Seal device was deployed using recommended techniques. After deployment, there was no evidence of an expanding hematoma or oozing. 4 days after discharge, the patient returned to the ED with right groin pain, swelling, and fever. Vital signs were: Temp 100.7 F, heart rate 76 beats/min, and blood pressure 120/70mmHg. The right groin was tender and erythematous. A non-floculent mobile 3x3 cm mass was palpated. White Blood Cell (WBC) count was 15,000 cells/dl and ultrasound revealed no pseudoaneurysm or fistula but a 2.1 x 1.4 x 1 cm heterogeneous area around the right common femoral artery. He was started on vancomycin 1gm IV every 12 hours per the Infectious Disease (ID) recommendation. After 3 days, blood cultures were negative x2, patient defervesced, and WBC count was stable (15,600 cells/dl). He was discharged home on PO clindamycin as per ID’s recommendation and scheduled for outpatient follow up. 5 days later, the patient returned to the ED with increasing pain and serosanguinous discharge from the right groin area. Repeat ultrasound showed evidence of 2 x 2 x 1.4 cm pseudoaneurysm with surrounding edema concerning for infection. Vascular surgery was consulted and the patient went for exploration of the right common femoral artery with debridement of the infected subcutaneous tissue and lymph nodes, debridement of the distal anterior wall of the common femoral artery with right greater saphenous vein patch angioplasty of the defect in the right common femoral artery, and right sartorius flap coverage of the common femoral artery repair. Femoral artery culture / operation room swab culture results returned positive for MRSA (Methicillin-resistant Staphylococcus aureus) sensitive to vancomycin. He was restarted on vancomycin 1.5 gm IV bid. Over the next few days, WBC count improved from 17,200 to 12,400 cells/dl and was discharged on vancomycin for 4 weeks with a wound vac.
Discussion

Bleeding and vascular complication rates with FACDs are similar to those that characterize manual compression (1.3% for VCDs vs 1.4% for manual compression) [8]. However, infection is a more common complication with use of FACDs. Bacteremia after PCI is reported in 18% immediately after procedure and 12% after 12hrs, although no sequel noted [9]. In a study of over 4000 patients with PCI, 0.64% had bacterial infection and 0.24% had septic complications [10]. The reported incidence of all catheter related infections was <1%; however, most of these were retrospective studies with a 5-10 day delay which most likely under-estimated the incidence of infectious complications [11].

Hematoma at the puncture site and presence of foreign material in the intravascular space and arterial wall serve as a nidus for infection, resulting in localized endarteritis, which is a risk factor for subsequent development of mycotic pseudoaneurysm. The median incubation period from FACD insertion to clinical presentation with access-site infection is 8 days [12]. 75% of these infections are from Staphylococcus aureus (82% MSSA and 18% MRSA), followed by gram negative rods (13%), coagulase negative Staphlococcus (5%) and others.

Brachial artery access, contamination of the sterile field by the patient or operator, indwelling sheaths connected to a pressurized heparin solution, repeat puncture of the ipsilateral femoral artery and leaving indwelling femoral wall sheaths for several days after the procedure have been associated with an increased incidence of infection [13-15].

Recent congestive heart failure was an independent predictor of postprocedural bacteremia [16]. Patient-related characteristics that predispose to an increased chance of infection include diabetes, obesity, advanced age, immuno-suppression and emergency patients, including shaving hair in holding area using a safety razor, use of betadine scrub and point of access site in procedure room.

Preventive strategy

Use of scrupulous sterile techniques including use of mask, cap and gown, electrical clippers for removal of hair, avoidance of endovascular graft access where possible, avoidance of femoral artery access ipsilateral to a prosthetic hip, avoidance of reused or sterilized catheters, contralateral puncture of the femoral artery for repeat procedures, particularly if a closure device has been recently used, should be performed, and the use of indwelling catheters after the procedure minimized wherever possible [11].

The 2% Chlorhexidine Gluconate/70% Isopropyl Alcohol formulation is preferred over betadine; it penetrates the first five layers of the stratum corneum, where 80% of skin-dwelling microorganisms reside. It should be allowed to air dry. ChloraPrep skin antiseptic meets the CDC’s Guidelines for the Prevention of Intravascular Catheter- related Infections, published in 2002. The Guidelines state “for cutaneous antisepsis a 2% chlorhexidine preparation is preferred” [17].

Treatment

If infection is suspected, it is recommended to collect at least two sets of blood cultures before antibiotics and doppler ultrasonography to evaluate for mycotic pseudoaneurysm. Empirical broad-spectrum antibiotics that should include coverage for MRSA (i.e., vancomycin) should be initiated soon with intravenous antibiotics for 2 to 4 weeks against identified organism. Duration of antibiotics may be extended up to 6 weeks for complicated cases (i.e., septic arthritis, endocarditis). Surgical debridement should be considered for all patients [18].

At our facility, starting January 1, 2012, in addition to the above sterile techniques, prior to deploying FACD, physicians and nurses have to prepare the groin region involving the intravascular sheath with a ChloraPrep applicator and use a different pair of gloves during deployment of FACD. So far, we have not encountered any complication of infection.

Conclusion

As mentioned above, the risk of infection from FACDs is extremely low, yet infection can still transpire. By instituting this new cutaneous antiseptic measure, hopefully we can further reduce this low incidence or even eliminate infection as a potential complication.

References

1) Reddy BK, Brewster PS, Walsh T, Burket MW, Thomas WJ, et al. (2004) Randomized comparison of rapid ambulation using radial, 4 French femoral access, or femoral access with Angioseal closure. Catheter Cardiovasc Inter 62: 143–149.
2) Arora N, Matheny ME, Sepke C, Resnic FS (2007) A propensity analysis of the risk of vascular complications after cardiac catheterization procedures with the use of vascular closure devices. Am Heart J 153: 606-611.
3) Davis C, VanRiper S, Longstreet J, Moscucci M (1997) Vascular complications of coronary interventions. Heart Lung 26: 118–127.
4) Hermiller J, Simonton C, Hinohara T, Lee D, Cannon L, et al. (2005) Clinical experience with a circumferential clip-based vascular closure device in diagnostic catheterization. J Invasive Cardiol 17: 504–510.
5) Exaire JE, Tcheng JE, Kereiakes DJ, Kleiman NS, Applegate RJ, et al. (2005) Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaprin, glycoprotein IIb/IIIa inhibitors and clopidogrel. Catheter Cardiovasc Interv 64: 369–372.
6) Applegate RJ, Sacrinty M, Kuchter MA, Gandhi SK, Baki TT, et al. (2006) Vascular complications with newer generations of Angioseal vascular closure devices. J Interv Cardiol 19: 67–74.
7) Eggebrecht H, Naber C, Woertgen U, Ringe S, Konorza TF, et al. (2003) Percutaneous suture-mediated closure of femoral access sites deployed through the procedure sheath: initial clinical experience with a novel vascular closure device. Catheter Cardiovasc Intern. 58: 313–321.
8) Applegate RJ, Sacrinty MT, Kutzer MA, Baki TT, Gandhi SK, et al. (2006) Propensity score analysis of vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention 1998-2003. Catheter Cardiovasc Interv 67: 556-562.

9) Ramsdale DR, Aziz S, Newall N, Palmer N, Jackson M. (2004) Bacteremia following complex percutaneous coronary intervention. J Invasive Cardiol 16: 632-634.

10) Samore MH, Wessolosky MA, Lewis SM, Shubrooks SJ Jr, Karchmer AW. (1997) Frequency, risk factors, and outcome for bacteremia after percutaneous transluminal coronary angioplasty. Am J Cardiol 1: 873-877.

11) Baddour LM, Bettmann MA, Bolger AF, Epstein AE, Ferreri P, et al. (2003) Nonvalvular cardiovascular device-related infections AHA. Circulation. 108: 2015-2031.

12) Johanning JM, Franklin DP, Elmore JR, Han DC. (2001) Femoral artery infections associated with percutaneous arterial closure devices. J Vasc Surg 34: 983-985.

13) Baim DS, Grossman W. (2000) Grossman’s Cardiac Catheterization Angiography and Intervention. 6th ed. Philadelphia, Pa: Lippincott Williams and Wilkins 35.

14) Shea KW, Schwartz RK, Gambino AT, Marzo KP, Cunha BA. (1995) Bacteremia associated with percutaneous transluminal coronary angioplasty. Cathet Cardiovasc Diagn 36: 5-10.

15) Wiener RS, Ong LS. (1989) Local infection after percutaneous transluminal coronary angioplasty: relation to early repuncture of ipsilateral femoral artery. Cathet Cardiovasc Diagn 16: 180–181.

16) Muñoz P, Blanco JR, Rodríguez-Creixéms M, García E, Delcan JL, et al. (2001) Bloodstream infections after invasive nonsurgical cardiology procedures. Arch Intern Med 161: 2110–2115.

17) O’Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, et al. (2002) Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep 51: 1-29.

18) Sohail MR, Khan AH, Holmes DR Jr, Wilson WR, Steckelberg JM, et al. (2005) Infectious complications of percutaneous vascular closure devices. Mayo Clin Proc 80: 1011-1015.